3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
18
Colonic Neoplasms
7
Rectal Neoplasms
5
Neoplasm Metastasis
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Unresectable Metastatic Colorectal Cancer
2
Ovarian Neoplasms
2
Gastrointestinal Neoplasms
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Prostatic Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locally-advanced Rectal Cancer
1
Gastroesophageal Adenocarcinoma
1
Endometrial Neoplasms
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
Docetaxel
43
enzalutamide
31
Prednisone
25
Abiraterone Acetate
24
Magnetic Resonance Spectroscopy
18
abiraterone
15
pembrolizumab
14
bicalutamide
14
Radiotherapy
14
Cyclophosphamide
13
darolutamide
12
Leuprolide
12
Goserelin
12
apalutamide
10
Ipilimumab
10
olaparib
9
Specimen Handling
9
Radiosurgery
9
Radiation
9
Injections
9
Biopsy
9
Pluvicto
8
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Carboplatin
7
sargramostim
6
fludarabine
6
cabazitaxel
6
Sirolimus
6
Nivolumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled